Janus 激酶抑制剂巴瑞替尼不是治疗 COVID-19 的理想选择。
Janus kinase inhibitor baricitinib is not an ideal option for management of COVID-19.
机构信息
Research Scholar, School of Pharmaceutical Sciences, Vels Institute of Science Technology and Advanced Studies, 600117, Chennai, India.
Department of Pharmaceutical Chemistry and Analysis, School of Pharmaceutical Sciences, Vels Institute of Science Technology and Advanced Studies, Chennai, India.
出版信息
Int J Antimicrob Agents. 2020 May;55(5):105967. doi: 10.1016/j.ijantimicag.2020.105967. Epub 2020 Apr 4.
Abstract
The Wuhan outbreak of novel Corona virus infection has been the global focus since December 2019. This infection has become a global pandemic. It is highly important to understand the virology of the pathogen and to explore the therapeutic options for management of this pandemic. Drug repurposing strategies are being considered for management of COVID 19. Among the identified drugs, Baricitinib has become a keen interest for researchers because of its ability to inhibit the viral assembly by the prevention of Clarithrin associated endocytosis. We tried to explore the reasons on why Baricitinib is not an ideal option for COVID 19.
摘要
自 2019 年 12 月以来，武汉新型冠状病毒感染疫情一直是全球关注的焦点。此次感染已成为全球性大流行。了解病原体的病毒学特性并探索这种大流行的治疗选择非常重要。正在考虑重新利用药物来治疗 COVID-19。在已确定的药物中，巴利昔替尼因其能够通过阻止克拉里丁相关内吞作用来抑制病毒组装而成为研究人员关注的焦点。我们试图探讨为什么巴利昔替尼不是治疗 COVID-19 的理想选择。
相似文献
1
Janus kinase inhibitor baricitinib is not an ideal option for management of COVID-19.
Int J Antimicrob Agents. 2020 May;55(5):105967. doi: 10.1016/j.ijantimicag.2020.105967. Epub 2020 Apr 4.
2
Baricitinib as potential treatment for 2019-nCoV acute respiratory disease.
Lancet. 2020 Feb 15;395(10223):e30-e31. doi: 10.1016/S0140-6736(20)30304-4. Epub 2020 Feb 4.
3
HiJAKing SARS-CoV-2? The potential role of JAK inhibitors in the management of COVID-19.
Sci Immunol. 2020 May 8;5(47). doi: 10.1126/sciimmunol.abc5367.
4
Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19.
Int Immunopharmacol. 2020 Sep;86:106749. doi: 10.1016/j.intimp.2020.106749. Epub 2020 Jul 1.
5
Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients.
EMBO Mol Med. 2020 Aug 7;12(8):e12697. doi: 10.15252/emmm.202012697. Epub 2020 Jun 24.
6
Pronounced benefits of JAK inhibition with baricitinib in COVID-19 pneumonia in obese but not lean subjects.
RMD Open. 2024 May 24;10(2):e004045. doi: 10.1136/rmdopen-2023-004045.
7
Baricitinib as rescue therapy in a patient with COVID-19 with no complete response to sarilumab.
Infection. 2020 Oct;48(5):767-771. doi: 10.1007/s15010-020-01476-7. Epub 2020 Jul 8.
8
Baricitinib: A Review of Pharmacology, Safety, and Emerging Clinical Experience in COVID-19.
Pharmacotherapy. 2020 Aug;40(8):843-856. doi: 10.1002/phar.2438. Epub 2020 Jul 27.
9
Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapy.
J Autoimmun. 2020 May;109:102442. doi: 10.1016/j.jaut.2020.102442. Epub 2020 Apr 2.
10
COVID-19: an unexpected indication for anti-rheumatic therapies?
Rheumatology (Oxford). 2020 Jun 1;59(6):1200-1203. doi: 10.1093/rheumatology/keaa194.
引用本文的文献
1
Examining efficacy and safety of ethyl acetate extract from as complementary therapy in COVID-19: A randomized, multicenter, controlled clinical trial.
Avicenna J Phytomed. 2024 Nov-Dec;14(6):699-710. doi: 10.22038/AJP.2024.24523.
2
A comprehensive review on pharmacologic agents, immunotherapies and supportive therapeutics for COVID-19.
Narra J. 2022 Dec;2(3):e92. doi: 10.52225/narra.v2i3.92. Epub 2022 Dec 8.
3
Therapeutic implications of current Janus kinase inhibitors as anti-COVID agents: A review.
Front Pharmacol. 2023 Mar 20;14:1135145. doi: 10.3389/fphar.2023.1135145. eCollection 2023.
4
Targeting Human Proteins for Antiviral Drug Discovery and Repurposing Efforts: A Focus on Protein Kinases.
Viruses. 2023 Feb 19;15(2):568. doi: 10.3390/v15020568.
5
Adverse effect signature extraction and prediction for drugs treating COVID-19.
Front Genet. 2022 Nov 4;13:1019940. doi: 10.3389/fgene.2022.1019940. eCollection 2022.
6
Identification of key molecules in COVID-19 patients significantly correlated with clinical outcomes by analyzing transcriptomic data.
Front Immunol. 2022 Aug 22;13:930866. doi: 10.3389/fimmu.2022.930866. eCollection 2022.
7
Recent clinical findings on the role of kinase inhibitors in COVID-19 management.
Life Sci. 2022 Oct 1;306:120809. doi: 10.1016/j.lfs.2022.120809. Epub 2022 Jul 13.
8
Enzymes in the time of COVID-19: An overview about the effects in the human body, enzyme market, and perspectives for new drugs.
Med Res Rev. 2022 Nov;42(6):2126-2167. doi: 10.1002/med.21919. Epub 2022 Jun 28.
9
Can anti-parasitic drugs help control COVID-19?
Future Virol. 2022 Mar. doi: 10.2217/fvl-2021-0160. Epub 2022 Mar 18.
10
Current challenges in different approaches to control COVID-19: a comprehensive review.
Bull Natl Res Cent. 2022;46(1):47. doi: 10.1186/s42269-022-00730-2. Epub 2022 Mar 3.
本文引用的文献
1
Imaging Profile of the COVID-19 Infection: Radiologic Findings and Literature Review.
Radiol Cardiothorac Imaging. 2020 Feb 13;2(1):e200034. doi: 10.1148/ryct.2020200034. eCollection 2020 Feb.
2
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.
Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11.
3
COVID-19: combining antiviral and anti-inflammatory treatments.
Lancet Infect Dis. 2020 Apr;20(4):400-402. doi: 10.1016/S1473-3099(20)30132-8. Epub 2020 Feb 27.
4
Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis.
RMD Open. 2020 Feb;6(1). doi: 10.1136/rmdopen-2019-001095.
5
Baricitinib as potential treatment for 2019-nCoV acute respiratory disease.
Lancet. 2020 Feb 15;395(10223):e30-e31. doi: 10.1016/S0140-6736(20)30304-4. Epub 2020 Feb 4.
6
Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.
JAMA. 2020 Mar 17;323(11):1061-1069. doi: 10.1001/jama.2020.1585.
7
Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding.
Lancet. 2020 Feb 22;395(10224):565-574. doi: 10.1016/S0140-6736(20)30251-8. Epub 2020 Jan 30.
8
Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study.
Lancet. 2020 Feb 15;395(10223):507-513. doi: 10.1016/S0140-6736(20)30211-7. Epub 2020 Jan 30.
9
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.
Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24.
10
Feasibility and biological rationale of repurposing sunitinib and erlotinib for dengue treatment.
Antiviral Res. 2018 Jul;155:67-75. doi: 10.1016/j.antiviral.2018.05.001. Epub 2018 May 16.
Zotero 插件